As many as 30 million doses of a Covid-19 vaccine could be made for Britain by September under a deal between Oxford University and the drugmaker Astrazeneca.
Ministers announced the target as they pledged £65.5 million in additional funding for the Oxford vaccine project. A second potential British vaccine, being developed at Imperial College London, will receive £18.5 million.
The Oxford team’s global licensing agreement with Astrazeneca, which is based in Cambridge, would cover the commercialisation and manufacturing of the jab, which still needs to pass safety and efficacy tests.
If the vaccine works, Astrazeneca has said that it will make it available at cost during the pandemic. It could later earn royalties if the virus became endemic like seasonal influenza.
Alok Sharma, the